Intranasal delivery of cannabidiol to treat central nervous system disorders

A method of treating a central nervous system (CNS) condition in a subject, comprising:

• administering intranasally a composition directly to a brain of the subject through direct nose-to-brain delivery, the composition comprising a therapeutically effective amount of Cannabidiol (CBD) in a solution or suspension form, delivered via an aerosol spray to an upper third of a nasal passage, wherein the composition travels directly to the brain of the subject, thereby providing greater bioavailability of CBD to the brain compared to oral administration and reducing potential drug-drug interactions associated with systemic delivery methods.

A method of treating a central nervous system (CNS) condition in a subject in need thereof, comprising of:

• administering intranasally a composition directly to a brain of the subject through direct nose-to-brain delivery using a pressurized container, pump, spray, atomizer, or nebulizer, the composition comprising a therapeutically effective amount of Cannabidiol (CBD) and a pharmaceutically acceptable excipient, delivered to an upper third of a nasal passage, wherein the composition travels directly to the brain of the subject, thereby providing greater bioavailability of CBD to the brain compared to oral administration and reducing potential drug-drug interactions associated with systemic delivery methods, wherein the pharmaceutically acceptable excipient is selected from the group consisting of a solvent, a dispersion media, a coating, an antibacterial or antifungal agent, an isotonic agent, an absorption delaying agent, an emulsifying agent, a penetration enhancer, a preservative, a buffer, water, saline, phosphate buffered saline, glycerol, ethanol, a sugar, a polyalcohol, a salt, and a combination thereof.